TW202302583A - Tyk2抑制劑及其用途 - Google Patents

Tyk2抑制劑及其用途 Download PDF

Info

Publication number
TW202302583A
TW202302583A TW111105572A TW111105572A TW202302583A TW 202302583 A TW202302583 A TW 202302583A TW 111105572 A TW111105572 A TW 111105572A TW 111105572 A TW111105572 A TW 111105572A TW 202302583 A TW202302583 A TW 202302583A
Authority
TW
Taiwan
Prior art keywords
substituted
unsubstituted
methyl
pharmaceutically acceptable
alkyl
Prior art date
Application number
TW111105572A
Other languages
English (en)
Chinese (zh)
Inventor
安潔莉 潘迪
格雷戈里 戴特斯奇
貝哈斯卡 恰德胡利
席特哈拉滿 滿歐傑維爾
馬赫許 躂卡爾
艾提沙亞滿尼 傑亞瑞杰 杜萊斯瓦買
蘇克許 卡爾娃
Original Assignee
英商蘇多生物科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商蘇多生物科學有限公司 filed Critical 英商蘇多生物科學有限公司
Publication of TW202302583A publication Critical patent/TW202302583A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
TW111105572A 2021-02-19 2022-02-16 Tyk2抑制劑及其用途 TW202302583A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163151287P 2021-02-19 2021-02-19
US63/151,287 2021-02-19
US202163193514P 2021-05-26 2021-05-26
US63/193,514 2021-05-26

Publications (1)

Publication Number Publication Date
TW202302583A true TW202302583A (zh) 2023-01-16

Family

ID=80786684

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111105572A TW202302583A (zh) 2021-02-19 2022-02-16 Tyk2抑制劑及其用途

Country Status (10)

Country Link
US (2) US12600721B2 (cg-RX-API-DMAC7.html)
EP (1) EP4294806A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024507253A (cg-RX-API-DMAC7.html)
KR (1) KR20230159420A (cg-RX-API-DMAC7.html)
AU (1) AU2022223497A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023016678A2 (cg-RX-API-DMAC7.html)
IL (1) IL305127A (cg-RX-API-DMAC7.html)
MX (1) MX2023009723A (cg-RX-API-DMAC7.html)
TW (1) TW202302583A (cg-RX-API-DMAC7.html)
WO (1) WO2022175746A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
US20260055121A1 (en) * 2022-08-24 2026-02-26 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
JP2025539787A (ja) * 2022-11-16 2025-12-09 ヴァーンウィ セラピューティクス,インコーポレイテッド Tyk2阻害剤
WO2024246602A1 (en) * 2023-05-26 2024-12-05 Sudo Biosciences Limited Fused azoled as tyk2 inhibitors and uses thereof
WO2026035922A1 (en) * 2024-08-08 2026-02-12 V6 Therapeutics, Inc. Selective jak2 inhibitors and uses thereof

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37650A (en) 1863-02-10 Improvement in apparatus for obtaining profiles of submarine beds
US36256A (en) 1862-08-19 Improvement in sewing-m ach ines
US47929A (en) 1865-05-30 Improved grapnel for wells
EP0124081A3 (en) 1983-05-02 1986-11-26 Merck & Co. Inc. New substituted cephalosporin sulfones as antiinflammatory and antidegenerative agents, pharmaceutical compositions containing the same and processes for making them
US5132301A (en) 1983-05-02 1992-07-21 Merck & Co., Inc. Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0541042A1 (de) 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE69819903T2 (de) 1997-08-09 2004-11-11 Smithkline Beecham P.L.C., Brentford Bicyclische verbindungen als liganden der 5-ht1 rezeptoren
DE10134721A1 (de) 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
JP2005509028A (ja) 2001-10-09 2005-04-07 バーテックス ファーマシューティカルズ インコーポレイテッド アスパラギン酸およびグルタミン酸誘導体ならびにそのジアゾケトン中間体を合成するための方法
KR100577179B1 (ko) 2001-10-30 2006-05-10 엘지전자 주식회사 유기 전계 발광 소자
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
CA2755297A1 (en) 2003-02-10 2004-08-26 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
CN100579965C (zh) 2003-02-10 2010-01-13 沃泰克斯药物股份有限公司 通过使n-芳基氨基甲酸酯与卤代杂芳基反应制备n-杂芳基-n-芳基胺的方法和类似方法
DE102004009238A1 (de) 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
ATE524182T1 (de) 2005-04-21 2011-09-15 Merck Serono Sa 2,3-substituierte pyrazinsulfonamide als crth2- hemmer
KR20080058436A (ko) 2005-10-13 2008-06-25 와이어쓰 글루탐산 유도체의 제조 방법
ATE541844T1 (de) 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
JP5546450B2 (ja) 2007-05-21 2014-07-09 オスラム オプト セミコンダクターズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 燐光発光金属錯体化合物、燐光発光金属錯体化合物を含有する発光素子、及び、燐光発光金属錯体化合物の製造法
TWI418608B (zh) 2007-09-28 2013-12-11 Osram Opto Semiconductors Gmbh 有機輻射發射元件
WO2009069132A2 (en) 2007-11-29 2009-06-04 Ramot At Tel Aviv University Ltd. Novel reverse transcriptase inhibitors
EP2231143B1 (en) 2007-12-13 2013-07-03 Merck Sharp & Dohme Corp. 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES
KR20100132550A (ko) * 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
US20130225527A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
GB0813403D0 (en) 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
EP2206712A1 (en) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
WO2010100144A1 (en) 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011056957A2 (en) 2009-11-06 2011-05-12 Chelsea Therapeutics, Inc. Enzyme inhibiting compounds
WO2011113060A2 (en) 2010-03-12 2011-09-15 Trana Discovery, Inc. Antiviral compounds and methods of use thereof
JP2013538821A (ja) 2010-09-24 2013-10-17 ランバクシー ラボラトリーズ リミテッド マトリックスメタロプロテイナーゼ阻害剤
WO2012079032A2 (en) 2010-12-09 2012-06-14 Trana Discovery, Inc. Compositions and methods of treating drug-resistant retroviral infections
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
GB201107176D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Pyrrolnitrin derivatives
WO2012172043A1 (en) 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
NO3175985T3 (cg-RX-API-DMAC7.html) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2874987A1 (en) 2012-06-01 2013-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9853756B2 (en) 2012-11-07 2017-12-26 Qualcomm Incorporated Multicast over wireless network with the assistance of power-efficient peer group discovery
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
EP2922841B8 (en) 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
CA2890935A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha.
WO2014120683A1 (en) 2013-01-29 2014-08-07 Children's Hospital Medical Center Small-molecule inhibitors targeting g-protein-coupled rho guanine nucleotide exchange factors
CN105188371A (zh) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
US9963452B2 (en) 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
WO2015013715A2 (en) 2013-07-26 2015-01-29 Thr Regents Of The University Of California C-h fluorination of heterocycles with silver (ii) fluoride
EP2873663A1 (en) * 2013-11-19 2015-05-20 Université de Strasbourg Novel uncharged reactivators against OP-inhibition of human acetylcholinesterase
WO2015129927A1 (en) 2014-02-26 2015-09-03 Kyorin Pharmaceutical Co., Ltd. Heterocyclic compounds
GB201405359D0 (en) 2014-03-25 2014-05-07 Univ Liverpool Synthetic process
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
WO2016138352A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2016149756A1 (en) 2015-03-23 2016-09-29 The University Of Melbourne Treatment of respiratory diseases
EP3290418B1 (en) 2015-04-29 2019-05-15 Wuxi Fortune Pharmaceutical Co., Ltd Janus kinase (jak) inhibitors
TW201705961A (zh) 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為jak抑制劑的2-(吡唑并吡啶-3-基)嘧啶衍生物
WO2016207345A1 (en) 2015-06-24 2016-12-29 Pierre Fabre Medicament 3-amino-pyrazin-2-yl carboxamide and 2-amino-pyridin-3-yl carboxamide derivatives as polo-like kinase 1 (plk-1) inhibitors for the treatment of cancer
WO2017005832A1 (en) 2015-07-09 2017-01-12 Solvay Specialty Polymers Italy S.P.A. Process for the synthesis of (per)fluoropolyether amines
KR101726059B1 (ko) 2015-07-28 2017-04-12 한양대학교 산학협력단 디피롤 유도체와 암모늄 염을 포함하는 브롬화수소 가스 검출용 조성물 및 이를 포함하는 브롬화수소 가스 검출용 색변환 센서
KR101766961B1 (ko) 2015-07-28 2017-08-09 한양대학교 산학협력단 트리페닐이미다졸 유도체와 암모늄 염을 포함하는 메틸아민 가스 검출용 조성물 및 이를 포함하는 메틸아민 가스 검출용 색변환 센서
GB201513481D0 (en) 2015-07-30 2015-09-16 Univ Manchester Inhibitor compounds
MX2018008169A (es) 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
BR112018070494A2 (pt) 2016-04-06 2019-01-29 Koninklijke Philips Nv carimbo para um processo de litografia por impressão, método de fabricação de um carimbo, kit de peças para a fabricação de um carimbo, método de formação de uma camada dotada de um padrão e uso de um carimbo
CN105820175B (zh) 2016-04-13 2019-09-20 四川大学 一种噻吩并嘧啶类化合物及其制备方法和应用
IL307931A (en) 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
CA3158951A1 (en) 2016-08-15 2018-02-22 Purdue Research Foundation 4-substituted aminoisoquinoline derivatives
CN107880038B (zh) 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
TWI763722B (zh) 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
WO2018151830A1 (en) * 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
GB201704327D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
AU2018243749A1 (en) 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
CN109020957B (zh) 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
US20210213014A1 (en) 2017-10-18 2021-07-15 Epizyme, Inc. Methods of using ehmt2 inhibitors in immunotherapies
AU2018353150B2 (en) 2017-10-18 2024-06-06 Epizyme, Inc. Methods of using EHMT2 inhibitors in treating or preventing blood disorders
GB201717260D0 (en) 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
MY202167A (en) 2017-11-21 2024-04-12 Bristol Myers Squibb Co Sulfone pyridine alkyl amide-substituted heteroaryl compounds
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
US11479555B2 (en) 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
WO2019209182A1 (en) 2018-04-25 2019-10-31 Nanyang Technological University Conjugated oligoelectrolytes as antimicrobial agents
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
JP2021536458A (ja) 2018-09-04 2021-12-27 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. アリール炭化水素レセプター・アンタゴニスト及び使用方法
JP2022508651A (ja) 2018-10-08 2022-01-19 レヴォリューション・メディスンズ,インコーポレイテッド 癌を処置するためのshp2阻害剤組成物および方法
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
US12098117B2 (en) 2018-12-11 2024-09-24 Duke University Compositions and methods for the treatment of cancer
EP3673920A1 (en) 2018-12-28 2020-07-01 Universität Wien Polyphenol-peptide conjugates for nuclear-targeted delivery
KR102943760B1 (ko) 2019-01-28 2026-03-26 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도
CN111484480B (zh) 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
GB201903085D0 (en) 2019-03-07 2019-04-24 Univ Oxford Innovation Ltd Passivation method
US20220177459A1 (en) 2019-04-02 2022-06-09 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators
WO2020222773A1 (en) 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
CN112079830B (zh) 2019-06-14 2023-12-22 上海翰森生物医药科技有限公司 含并环类衍生物抑制剂、其制备方法和应用
KR102877616B1 (ko) 2019-07-01 2025-10-28 삼성디스플레이 주식회사 조성물 및 이를 포함한 유기 발광 소자
WO2021001739A1 (en) 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Translational enhancers and related methods
WO2021014453A1 (en) 2019-07-24 2021-01-28 Sol-Gel Technologies Ltd. Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
IL291452B1 (en) 2019-09-18 2026-06-01 Bristol Myers Squibb Co Dosage forms for TYK2 inhibitors
CN112851579A (zh) 2019-11-27 2021-05-28 衡阳师范学院 用于铜催化卤代芳烃偶联反应的配体化合物、催化体系和偶联反应
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US20230128972A1 (en) 2020-01-31 2023-04-27 Atomwise Inc. Anat Inhibitors and Methods of Use Thereof
ES2981764T3 (es) 2020-03-11 2024-10-10 Beijing Innocare Pharma Tech Co Ltd Compuestos heterocíclicos para inhibir las actividades de TYK2
KR20230004771A (ko) 2020-04-28 2023-01-06 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물
IL298966A (en) 2020-06-11 2023-02-01 Betta Pharmaceuticals Co Ltd Bicyclic compound and application thereof
CN115667246B (zh) 2020-07-24 2024-08-23 上海翰森生物医药科技有限公司 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
CN113968846A (zh) 2020-07-24 2022-01-25 上海翰森生物医药科技有限公司 一种哒嗪类衍生物的盐、晶型及其制备方法和应用
US20220144842A1 (en) 2020-11-04 2022-05-12 Eternity Bioscience Inc. Irak inhibitors, preparation method and medicinal uses thereof
US20230416225A1 (en) 2020-11-09 2023-12-28 Merck Sharp & Dohme Llc Diaminopyrimidine carboxamide inhibitors of hpk1
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
WO2022175745A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
JP2022143679A (ja) 2021-03-18 2022-10-03 株式会社リコー 光電変換素子、電子機器、及び電源モジュール
US12054506B2 (en) 2021-03-19 2024-08-06 Singular Genomics Systems, Inc. Reducing agents and uses thereof
WO2022226349A1 (en) 2021-04-22 2022-10-27 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US12560054B2 (en) 2021-04-30 2026-02-24 Board Of Regents, The University Of Texas System Use of carboxylates for carbon sequestration, improved oil recovery, and hydrogen storage and reproduction
KR20240008338A (ko) 2021-05-14 2024-01-18 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
US20240317718A1 (en) 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
KR20240007242A (ko) 2021-05-14 2024-01-16 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
PE20250262A1 (es) 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos
EP4337650A1 (en) 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
WO2023227946A1 (en) 2022-05-27 2023-11-30 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
US20260055121A1 (en) 2022-08-24 2026-02-26 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2024246602A1 (en) 2023-05-26 2024-12-05 Sudo Biosciences Limited Fused azoled as tyk2 inhibitors and uses thereof
IL324864A (en) 2023-05-26 2026-01-01 Sudo Biosciences Ltd Compressed azines as tyk2 inhibitors and their uses
WO2025114761A1 (en) 2023-11-29 2025-06-05 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
IL328235A (en) 2023-11-29 2026-07-01 Sudo Biosciences Ltd TYK2 inhibitors and their uses

Also Published As

Publication number Publication date
WO2022175746A1 (en) 2022-08-25
AU2022223497A1 (en) 2023-09-21
US20260193259A1 (en) 2026-07-09
WO2022175746A8 (en) 2023-10-19
BR112023016678A2 (pt) 2023-11-14
KR20230159420A (ko) 2023-11-21
MX2023009723A (es) 2023-10-30
US20240199610A1 (en) 2024-06-20
IL305127A (en) 2023-10-01
US12600721B2 (en) 2026-04-14
JP2024507253A (ja) 2024-02-16
EP4294806A1 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
US12122785B2 (en) Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors
US12103937B2 (en) Substituted pyridines and pyridazines as TYK2 inhibitors
US12600721B2 (en) TYK2 inhibitors and uses thereof
WO2022175745A1 (en) Tyk2 inhibitors and uses thereof
US20240124440A1 (en) Tyk2 inhibitors and uses thereof
TW202511266A (zh) Tyk2抑制劑及其用途
US20260055121A1 (en) Tyk2 inhibitors and uses thereof
CN117377669A (zh) Tyk2抑制剂及其用途
WO2025114760A1 (en) Tyk2 inhibitors and uses thereof
WO2025114761A1 (en) Tyk2 inhibitors and uses thereof
CN117120440A (zh) Tyk2抑制剂及其用途
CA3208507A1 (en) Tyk2 inhibitors and uses thereof
EA052918B1 (ru) Ингибиторы tyk2 и их применение